Electra Therapeutics (NASDAQ:ETRA) Director Purchases $164,800.00 in Stock

Electra Therapeutics, Inc. (NASDAQ:ETRA) Director Orbimed Advisors Llc purchased 20,000 shares of the company’s stock in a transaction on Monday, November 9th. The stock was bought at an average price of $8.24 per share, for a total transaction of $164,800.00. Following the completion of the purchase, the director directly owned 5,234,578 shares of the company’s stock, valued at $43,132,922.72. The trade was a 0.38% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Orbimed Advisors Llc also recently made the following trade(s):

• On Tuesday, November 10th, Orbimed Advisors Llc bought 22,700 shares of Electra Therapeutics stock. The stock was bought at an average cost of $8.45 per share, for a total transaction of $191,815.00.
• On Friday, November 6th, Orbimed Advisors Llc purchased 49,416 shares of Electra Therapeutics stock. The shares were bought at an average price of $7.85 per share, for a total transaction of $387,915.60.
• On Thursday, November 5th, Orbimed Advisors Llc purchased 156,091 shares of Electra Therapeutics stock. The shares were bought at an average price of $7.31 per share, for a total transaction of $1,141,025.21.
• On Wednesday, November 4th, Orbimed Advisors Llc acquired 71,367 shares of Electra Therapeutics stock. The shares were acquired at an average cost of $7.53 per share, for a total transaction of $537,393.51.
• On Tuesday, November 3rd, Orbimed Advisors Llc bought 245,113 shares of Electra Therapeutics stock. The stock was acquired at an average cost of $7.86 per share, with a total value of $1,926,588.18.
• On Monday, September 21st, Orbimed Advisors Llc bought 1,333,333 shares of Electra Therapeutics stock. The stock was acquired at an average cost of $15.00 per share, with a total value of $19,999,995.00.

Electra Therapeutics Stock Performance

Shares of ETRA opened at $9.11 on Friday. Electra Therapeutics, Inc. has a fifty-two week low of $6.86 and a fifty-two week high of $15.50.

Electra Therapeutics (NASDAQ:ETRA) last released its quarterly earnings results on Thursday, November 12th. The company reported ($3.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.76) by ($1.71). As a group, research analysts expect that Electra Therapeutics, Inc. will post -3.45 EPS for the current year.

Analyst Upgrades and Downgrades

ETRA has been the topic of several analyst reports. Wall Street Zen upgraded Electra Therapeutics to a “hold” rating in a research note on Saturday, September 26th. Jefferies Financial Group started coverage on Electra Therapeutics in a research note on Tuesday, October 13th. They set a “buy” rating and a $32.00 price target for the company. Cantor Fitzgerald initiated coverage on Electra Therapeutics in a report on Tuesday, October 13th. They set an “overweight” rating for the company. TD Cowen assumed coverage on Electra Therapeutics in a report on Tuesday, October 13th. They set a “buy” rating for the company. Finally, JPMorgan Chase & Co. started coverage on shares of Electra Therapeutics in a research report on Thursday, October 22nd. They issued an “overweight” rating and a $36.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $33.50.

About Electra Therapeutics

Electra Therapeutics, Inc. (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function. Electra’s lead investigational product is ELA026, an antibody targeting SIRPα, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.